British journal of pharmacology · 2026
NMDA receptor subunit-dependent analysis of radiprodil inhibition in neonatal male rat substantia nigra dopaminergic neurons.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Bangyuan, Gibb Alasdair J
Аннотация
BACKGROUND AND PURPOSE: Radiprodil is a GluN2B subunit selective NMDA receptor negative allosteric modulator which is currently under clinical investigation as a possible anti-epileptic drug for paediatric use. Our goal was to investigate the inhibition of dopaminergic neuron NMDA responses by radiprodil.
EXPERIMENTAL APPROACH: Whole-cell and outside-out patch-clamp recordings from substantia nigra dopaminergic neurons in acute mid-brain slices from neonatal male rats were used to investigate radiprodil action. Radiprodil action was analysed using a 'hypercube' model with explicit receptor GluN2B subunit-dependent binding steps for agonist and antagonist and allosteric constant describing the effect of radiprodil on agonist binding and receptor channel gating and a 2nd binding site for radiprodil that may mediate partial reversal of the radiprodil inhibitory effect.
KEY RESULTS: Radiprodil produced a concentration-dependent partial inhibition with about 40% maximum at concentrations between 30 and 100 nM. Surprisingly, at higher radiprodil concentrations, the inhibition decreased. Radiprodil (30 nM) also caused a 12% decrease in single channel current.
CONCLUSION AND IMPLICATIONS: The results are described by a two-binding site model assuming radiprodil inhibits receptor activation by binding to the GluN2B subunit whilst reducing inhibition by binding to a secondary site, which may or may not be on the receptor. We conclude that NMDA receptor allosteric modulators such as radiprodil can display a combination of inhibitory and reversal of inhibitory effects, depending on drug concentration and receptor subunit combinations. These properties may give some allosteric drugs a unique profile of action, which could be advantageous in some clinical circumstances.
EXPERIMENTAL APPROACH: Whole-cell and outside-out patch-clamp recordings from substantia nigra dopaminergic neurons in acute mid-brain slices from neonatal male rats were used to investigate radiprodil action. Radiprodil action was analysed using a 'hypercube' model with explicit receptor GluN2B subunit-dependent binding steps for agonist and antagonist and allosteric constant describing the effect of radiprodil on agonist binding and receptor channel gating and a 2nd binding site for radiprodil that may mediate partial reversal of the radiprodil inhibitory effect.
KEY RESULTS: Radiprodil produced a concentration-dependent partial inhibition with about 40% maximum at concentrations between 30 and 100 nM. Surprisingly, at higher radiprodil concentrations, the inhibition decreased. Radiprodil (30 nM) also caused a 12% decrease in single channel current.
CONCLUSION AND IMPLICATIONS: The results are described by a two-binding site model assuming radiprodil inhibits receptor activation by binding to the GluN2B subunit whilst reducing inhibition by binding to a secondary site, which may or may not be on the receptor. We conclude that NMDA receptor allosteric modulators such as radiprodil can display a combination of inhibitory and reversal of inhibitory effects, depending on drug concentration and receptor subunit combinations. These properties may give some allosteric drugs a unique profile of action, which could be advantageous in some clinical circumstances.